![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, April 10, 2023 4:02:48 PM
But the only real issue is whether the science is as compelling as you once found it to be. Is it still? Because only if it is should NNVC investors start counting their chickens or worrying about things like who gets what. If it isn't then Diwan has only created a new way to get money from NNVC to Diwan.
The concept of a nanoparticle trap / dismemberment of nano-sized viral particles seems sound, and other groups have shown similar concepts seem to work well in preclinical studies. NNVC presented some data that seemed to show good safety and effectiveness in their preclinical models, so yeah, I thought it was worth a shot as a high risk, high reward biotech investment. Seeing how NNVC never makes any progress, though, it hasn't been good to put more good money after bad.
The real questions with NNVC technology are:
(1) Can they make the drugs consistently at decent volume and cost?
(2) Are they safe and effective in humans? Hopefully we will begin to see some answers to these critical questions via Covid trials in India.
and of course at this point one has to continue to wonder
(3) What is the deal with Anil? Is he really trying to get his drugs tested in humans and to market, or is something else going on?
Maybe he plans on being a runaway fugitive, and is planning to move to India and do his thing there with whatever pieces are left of NNVC (really never was much there except promising preclinical work and some licenses) if things turn out as badly as many have predicted, and it really is all a big scam.
It could be a while to get these answers, but as with all things, time will tell.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM